## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT HT//W

RECEIVED

re Application of:

Abdolmohammed Rostami et al.

**Application No.:** 09/943,688

Group Art Unit: 1651

SEP 2 0 2002

Filed: 08/31/2001

Examiner: M. Flood

TECH CENTER 1600/2900

Title: Use of Bowman Birk Inhibitor for the Treatment of MS and Other Autoimmune Diseases

Assistant Commissioner for Patents Washington, DC 20231

## RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement mailed August 19, 2002, Applicants elect to prosecute the subject matter of Group I, identified by Claims 1-13.

It is respectfully noted that Claims 14-19 (Group II) have been cancelled, without prejudice, and, therefore, are not pending in the above-identified application.

Should the Examiner have any questions or comments regarding Applicants' amendments or response, (s)he is asked to contact Applicants' undersigned representative at (215) 575-7034. Please direct all correspondence to the below-listed address.

If there are any fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0979.

Respectfully submitted,

Evelyn H! McConathy

Registration No. 35,279

Date: September 17, 2002 DILWORTH PAXSON LLP 3200 Mellon Bank Center 1735 Market Street Philadelphia, PA 19103-7595 Tel. (215) 575-7000 Fax (215) 575-7200

Late Mailed: 09/17/02

466012 1